PGR and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC)—which is characterized by lack of substantial expression of ER, its downstream effector progesterone receptor (PR), and HER2—has few available targeted therapeutics, is highly metastatic, and associates with poor patient outcome (12).